Why It Matters
Surescripts, a healthcare technology company central to Medicare's electronic prescribing infrastructure, has terminated its in-house lobbying registration as of June 30, according to a recent disclosure filing.
Surescripts' network is central to Medicare Part D e-prescribing mandates under Medicare Improvements for Patients and Providers Act (MIPPA) and Health Information Technology for Economic and Clinical Health Act (HITECH) and to the Centers for Medicare & Medicaid Services (CMS) regulations.
Deanne Primozic, the Vice President of Policy and Federal Affairs, was the lobbyist listed on the termination filing.
By The Numbers
The company reported $10,000 in lobbying expenditures during the second quarter of 2025 and maintained activity through external firms in subsequent years.
Broader Context
Surescripts operates a technology-neutral platform managing prescriptions between providers and pharmacies. The company provides e-prescribing for controlled substances with safety and compliance tools, medication history sharing, electronic prior authorization services, and real-time prescription benefit tools showing patients' out-of-pocket drug costs at the point of prescribing. It also provides health information exchange and interoperability services connecting pharmacies, EHR vendors, health plans, and prescribers.
CMS mandated electronic prescribing of controlled substances for controlled substance prescriptions written for beneficiaries in long-term care facilities effective January 1, 2025. In April 2026, CMS published a proposed rule extending interoperability requirements to cover electronic prior authorization for drugs.
Surescripts actively engages with CMS proposed rules on interoperability and prior authorization for Medicare Advantage and Medicaid, and works with the Office of the National Coordinator for Health Information Technology on interoperability standards.
The Federal Trade Commission (FTC) sued Surescripts in 2019 for allegedly using exclusive loyalty pricing contracts to maintain monopolies in e-prescribing routing and eligibility markets. Surescripts later settled with the FTC, eliminating loyalty provisions from its contracts.
The Bottom Line
Companies under private equity ownership frequently optimize their lobbying footprint by consolidating in-house teams and relying on specialized external firms for targeted advocacy on specific regulatory issues.
Spot something wrong? Report an issue with this article